anti-CD137 (human), mAb (4B4-1)白细胞分化抗原137 (人), 单克隆抗体 (4B4-1) 价格￥3500 起批量≥1盒 最小起订1盒 供货总量200盒 发货地址江苏省南京市 建议售价￥3500/盒 更新日期2024年08月30日 产品规格100 μg 洽谈立即询价查看联系方式 ...
Anti-CD137 mAb treatment inhibits experimental autoimmune uveitis by limiting expansion and increasing apoptotic death of uveitogenic T cells. Invest Ophthalmol Vis Sci. 2005; 46 :596–603.Shao H, Fu Y, Liao T, et al. Anti-CD137 mAb Treatment Inhibits Experimental Autoimmune Uveitis by ...
CD137—BioXCell热销产品InVivoMAb anti-mouse 4-1BB (CD137)(货号:BE0239) 克隆号3H3单克隆抗体与小鼠4-1BB反应,小鼠4-1BB是TNF受体超家族成员,也称为CD137。4-1BB是由T淋巴细胞、NK细胞、树突细胞、粒细胞和肥大细胞表达的39 kDa跨膜蛋白。在结合其配体4-1BBL后,4-1BB通过激活NF-κB、c-Jun和...
化学名:CD137,CLONE:S16,MABANTI-HUMAN:PARAFFIN,IHC 英語化学名:CD137,CLONE:S16,MABANTI-HUMAN:PARAFFIN,IHC 别名: CD137,CLONE:S16,MABANTI-HUMAN:PARAFFIN,IHC CAS番号: 分子式: 分子量:0 EINECS: Mol File:Mol FileBrowse by Nationality CD137,CLONE:S16,MABANTI-HUMAN:PARAFFIN,IHC Suppliers ...
The agonistic anti-CD137 mAb was able to elevate by about 20% of the DC-mediated inhibition of tumor growth in five tumor cell lines. These results indicate that the appliance of anti-CD137 mAb might be used as a new strategy for tumor immunotherapy. Cellular & Molecular Immunology. 2004;...
Apparently, anti-CD137 mAb rapidly induced activation of donor T cells and sustained their activation status under the inflammatory condition triggered by irradiation. When given on day 12 after irradiation and BMT, anti-CD137 mAb could still exacerbate GVHD, but when given on day 30, it could...
英文别名: InVivoMab anti-mouse 4-1BB (CD137)中文名: 中文别名: CBNumber: CB45648030 分子式: 分子量: 0 MOL File: Mol file 化学性质 安全信息 用途 供应商 5 InVivoMab anti-mouse 4-1BB (CD137)化学性质 安全信息InVivoMab anti-mouse 4-1BB (CD137)性质、用途与生产工艺 InVivoMab anti-...
InVivoMab anti-mouse 4-1BB (CD137)| 基本信息更多信息 中文名称: 中文同义词: 英文名称:InVivoMab anti-mouse 4-1BB (CD137) 英文同义词:InVivoMab anti-mouse 4-1BB (CD137) CAS号: 分子式: 分子量:0 EINECS号: 信息错误报告 您的Email: ...
brought in proximity. Even under saturating conditions MCLA-145 is not able to activate CD137 without the presence of a neighboring cell expressing PD-L1. In addition, T cell activation required signal 1 (i.e., TCR stimulation via CD3 mAb or polyclonal activation). Furthermore, we show that...
Several studies have demonstrated induction of tumour immunity by treatment with agonistic CD137 mAb (Dubrot et al., 2010; Gauttier et al., 2014; Kim et al., 2001; McMillin et al., 2006; Melero et al., 1997; Miller et al., 2002; Sallin et al., 2014; Taraban et al., 2002; Un...